About Me

I am Associate Professor in Management Science (with tenure) at the Saïd Business School (SBS), University of Oxford. At SBS, I teach courses in Analytics and have served as Associate Academic Director of the MBA program. In 2019, I was named as one of the World's Best 40 Business School Professors Under 40 by Poets & Quants. I am also a Turing Fellow of The Alan Turing Institute (the UK's national research institute for data science & AI), and a Fellow of St Cross College, Oxford. 

Prior to Oxford, I was on the faculty of the Hong Kong University of Science & Technology (HKUST). I completed my Ph.D. and M.S. degrees from the University of California at Berkeley, and my B.S. degree from Northwestern University. 

My research interests cover operations research, data science and operations management. On the methodological side, I focus on developing prescriptive analytics methods that converts data into business decisions. My current interests include methods for dimensionality reduction for stochastic optimization and algorithmic fairness in data-driven optimization.  

On the applications side, my work in operations management aims to develop both managerial insights and analytics solutions to complex problems arising in:

- Supply chain management;

- Digital retail operations;

- Sustainable, smart transportation & energy;

- The sharing economy;

- Operations & marketing interface.

Some of my recent work focuses on the smart city context (see the discussion paper, published in M&SOM). This line of work has been recognized by the M&SOM Best Paper Award (twice), the INFORMS Transportation Science & Logistics (TSL) Best Paper Award, and the INFORMS Energy & Natural Resources (ENRE) Young Researcher Prize. 

Recent Updates
  • It is my great honor to be named a Turing Fellow of The Alan Turing Institute, the UK's national research institute for data science & AI.

  • New working paper on Managing Two-Dose COVID-19 Vaccine Rollouts with Limited Supply (with Tinglong Dai and Chris Tang). Facing limited COVID vaccine supply and racing against time, different countries embrace different vaccine rollout policies: holding back stock for second doses (EU), releasing all stock (US) and stretching leadtimes (UK). Who is right? Could a single-dose vaccine (e.g., Johnson & Johnson) save the day?

​​